FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)
PMA: P210019
·
Supplement: S001
·
Decision Dec 20, 2022
Classifications
1
FEI Numbers
27
Registration Numbers
27
Basic Information
- Device Name
- Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)
- Trade Name
- ADVIA Centaur Anti-HBc Total 2 (HBcT2), ADVIA Centaur® HBcT2 Quality Control (HBcT2 QC)
- PMA Number
- P210019
- Supplement Number
- S001
- Device Class
- FDA Class 3
- Product Code
- LOM
- Generic Name
- Test, hepatitis b (b core, be antigen, be antibody, b core igm)
- Medical Specialty
- Unknown
- Advisory Committee
- Microbiology
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- December 20, 2022
- Date Received
- August 1, 2022
- Supplement Type
- Normal 180 Day Track
- Supplement Reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Expedited Review
- N
Advisory Committee Statement
Approval for the use of the ADVIA Centaur Anti-HBc Total 2 (HBcT2) assay on the ADVIA Centaur CP.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| LOM | Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm) | FDA class 3 | Unknown |